Compare AANJANEYA LIFECARE with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS ELDER PHARMA DR. DATSONS LABS/
ELDER PHARMA
 
P/E (TTM) x -10.9 -0.2 - View Chart
P/BV x 0.2 0.1 160.9% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 DR. DATSONS LABS   ELDER PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
ELDER PHARMA
Jun-14
DR. DATSONS LABS/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs126380 33.1%   
Low Rs31188 16.4%   
Sales per share (Unadj.) Rs133.0491.2 27.1%  
Earnings per share (Unadj.) Rs0.2-3.2 -4.8%  
Cash flow per share (Unadj.) Rs6.614.4 45.9%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs128.8376.5 34.2%  
Shares outstanding (eoy) m31.6620.54 154.1%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.60.6 101.8%   
Avg P/E ratio x516.1-89.3 -578.2%  
P/CF ratio (eoy) x11.819.7 60.1%  
Price / Book Value ratio x0.60.8 80.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m2,4775,833 42.5%   
No. of employees `000NANA-   
Total wages/salary Rs m562,179 2.6%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m4,21110,089 41.7%  
Other income Rs m79257 30.7%   
Total revenues Rs m4,28910,346 41.5%   
Gross profit Rs m569-792 -71.8%  
Depreciation Rs m204361 56.6%   
Interest Rs m4302,756 15.6%   
Profit before tax Rs m13-3,653 -0.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m6125 4.9%   
Profit after tax Rs m5-65 -7.3%  
Gross profit margin %13.5-7.8 -172.0%  
Effective tax rate %48.0-3.4 -1,402.0%   
Net profit margin %0.1-0.6 -17.6%  
BALANCE SHEET DATA
Current assets Rs m6,8529,240 74.2%   
Current liabilities Rs m6,7119,998 67.1%   
Net working cap to sales %3.3-7.5 -44.6%  
Current ratio x1.00.9 110.5%  
Inventory Days Days16146 347.3%  
Debtors Days Days31860 531.3%  
Net fixed assets Rs m3,67310,124 36.3%   
Share capital Rs m317206 153.9%   
"Free" reserves Rs m3,7615,582 67.4%   
Net worth Rs m4,0787,734 52.7%   
Long term debt Rs m1,6714,889 34.2%   
Total assets Rs m12,63322,882 55.2%  
Interest coverage x1.0-0.3 -316.5%   
Debt to equity ratio x0.40.6 64.8%  
Sales to assets ratio x0.30.4 75.6%   
Return on assets %3.411.8 29.3%  
Return on equity %0.1-0.8 -13.9%  
Return on capital %7.722.3 34.4%  
Exports to sales %22.93.0 753.4%   
Imports to sales %14.30.4 3,346.3%   
Exports (fob) Rs m964307 314.4%   
Imports (cif) Rs m60243 1,396.5%   
Fx inflow Rs m964307 314.4%   
Fx outflow Rs m607125 484.5%   
Net fx Rs m357181 196.9%   
CASH FLOW
From Operations Rs m1,34511,754 11.4%  
From Investments Rs m-2,256-561 402.4%  
From Financial Activity Rs m-1,200-6,762 17.7%  
Net Cashflow Rs m-2,1114,432 -47.6%  

Share Holding

Indian Promoters % 4.5 39.6 11.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 7.5 -  
FIIs % 1.4 16.8 8.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 36.1 260.7%  
Shareholders   20,807 16,479 126.3%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare DR. DATSONS LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

Shares of Oxygen Suppliers in Focus Amid Rising Demand for Oxygen (Company Info)

Apr 20, 2021

In this article, we discuss the hype around Oxygen supplier stocks and a little known NBFC company, which has rallied 150% in less than a month.

Nazara Technologies IPO: Should You Apply? (IPO)

Mar 17, 2021

Should you bet on this gaming company backed by ace investor Rakesh Jhunjhunwala?

Shares of Oxygen Suppliers in Focus Amid Rising Demand for Oxygen (Company Info)

Apr 20, 2021

In this article, we discuss the hype around Oxygen supplier stocks and a little known NBFC company, which has rallied 150% in less than a month.

Nazara Technologies IPO: Should You Apply? (IPO)

Mar 17, 2021

Should you bet on this gaming company backed by ace investor Rakesh Jhunjhunwala?

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 8-QTR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS